Therapeutic approaches in glycogen storage disease type II/pompe disease-Reference-Cited by-同舟云学术

Therapeutic approaches in glycogen storage disease type II/pompe disease

Published:2008-10 Issue:4 Volume:5 Page:569-578
ISSN:1933-7213
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Schoser Benedikt,Hill Victoria,Raben Nina

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Link

http://www.springerlink.com/index/pdf/10.1016/j.nurt.2008.08.009

Reference67 articles.

1. Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998;79: 69–72.

2. Engel AG, Hirschhorn R, Huie ML. Acid maltase deficiency. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill, 2003: 1559–1586.

3. Winkel LP, Hagemans ML, Van Doorn PA, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 2005;252: 875–884.

4. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148: 671–676.

5. Griffin JL. Infantile acid maltase deficiency. III. Ultrastructure of metachromatic material and glycogen in muscle fibers. Virchows Arch B Cell Pathol Incl Mol Pathol 1984;45: 51–61.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report;Italian Journal of Pediatrics;2022-03-28

2. To detect potential pathways and target genes in infantile Pompe patients using computational analysis;BioImpacts;2022-01-22

3. Therapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease;Biomedicine & Pharmacotherapy;2021-05

4. Glycogen storage in a zebrafish Pompe disease model is reduced by 3-BrPA treatment;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2020-05

5. The Respiratory Phenotype of Pompe Disease Mouse Models;International Journal of Molecular Sciences;2020-03-24